This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Vasoo, S Articles by Fong, K-Y Search for Related Content PubMed PubMed Citation Articles by Vasoo, S Articles by Fong, K-Y Social Bookmarking                         What's this?

Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: disease activity and the use of cytotoxic drugs

Division of Rheumatology, Department of Medicine, National University Hospital, Singapore; Department of Medicine, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074, Singaporesheilav{at}nuh.com.sg

J Thumboo

K-Y Fong

Division of Rheumatology, Department of Medicine, National University Hospital, Singapore

Thrombotic thrombocytopenicpurpura (TTP) is a rare and occasionally fatal haematologic disorder that can coexist with systemic lupus erythematosus (SLE) and other autoimmune diseases. We identified all cases of TTP seen in our institution over a 3 year period using a computerized database. We found that SLE activity (measured by the SLE Disease Activity Index) and TTP activity ran a parallel course in three patients with coexistent SLE and TTP. TTP in these three patients, although refractory to plasmapheresis, responded to cytotoxic therapy. These observations further support an autoimmune contribution to the pathogenesis of some cases of TTP. A literature review revealed that mortality in SLE patients with more severe, refractory TTP treated with plasmapheresis and cytotoxics, may not be higher than in patients responding to plasmapheresis alone (who are likely to have milder disease). These data suggest that cytotoxics may have a role in treatment of patients with active SLE and TTP refractory to plasmapheresis.

Key Words: immunosuppressive agents • lupus erythematosus systemic • purpura • thrombotic thrombocytopenic

Lupus, Vol. 11, No. 7, 443-450 (2002)
DOI: 10.1191/0961203302lu224oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F. Yu, Y. Tan, and M.-H. Zhao Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome Nephrol. Dial. Transplant., August 23, 2009; (2009) gfp421v1. [Abstract] [Full Text] [PDF]

				P. Letchumanan, H.-J. Ng, L.-H. Lee, and J. Thumboo A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus Rheumatology, April 1, 2009; 48(4): 399 - 403. [Abstract] [Full Text] [PDF]

				S. Kwok, J. Ju, C. Cho, H. Kim, and S. Park Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study Lupus, January 1, 2009; 18(1): 16 - 21. [Abstract] [PDF]

				B. Parker and I. Bruce High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus Lupus, June 1, 2007; 16(6): 387 - 393. [Abstract] [PDF]

				V. Majithia and V. Harisdangkul Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: a frequent and severe consequence of active disease Rheumatology, September 1, 2006; 45(9): 1170 - 1171. [Full Text] [PDF]